1. Orphan Drug Act of 1983, Public Law 97-414, Stat. 2049 (1983) amended by public law 98-551 (1984) to add a numeric prevalence threshold.
2. Utilizing innovative statistical methods and trial designs in rare diseases. In: health policy. https://healthpolicy.duke.edu/sites/default/files/2020-03/backgrounder_10_11_16.pdf. Accessed 23 Dec 2021.
3. Information packet, rare diseases day 2022. In: Rare disease day. https://download2.rarediseaseday.org/2022/campaign_materials/infopack_2022.pdf Accessed 23 Dec 2021.
4. Beckman RA, Clark JC, Chen C. Integrating predictive biomarkers and classifiers into oncology drug development programs. Nat Rev Drug Discovery. 2011;10:735–49.
5. Schwartz, J. Research in rare disease: the nature and extent of evidence needed for decision. In: 51st annual meeting of the Drug information Association, session #318 (track 17), 2015, Washington, DC.